INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The research library / Market
Market / SOURCE-DATED ANALYSIS

Generic GLP-1 development is a quality question

FDA’s workshop page scheduled a September 23–24 program on generic GLP-1 characterization, manufacturing quality, bioequivalence and drug-device issues.

What changed

FDA’s workshop page scheduled a September 23–24 program on generic GLP-1 characterization, manufacturing quality, bioequivalence and drug-device issues.

What the evidence does not settle

Page current as of July 23. Listing an event does not establish attendance, final guidance or product approval.

Evidence record

Event date: 2026-09-23. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.

  1. Original source ↗

Revision history

29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.

THE MODERN DOSING WEEKLY

The peptide news
that changes your week.

Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.